253 related articles for article (PubMed ID: 20937224)
1. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Qin X; Liu C; Zhou Y; Wang G
Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1366-72. PubMed ID: 20937224
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Zhang P; Su DM; Liang M; Fu J
Mol Immunol; 2008 Mar; 45(5):1470-6. PubMed ID: 17920123
[TBL] [Abstract][Full Text] [Related]
4. [Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway].
Zhu H; Liu D; Deng S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Oct; 37(10):891-896. PubMed ID: 34670665
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Li S; Ji J; Zhang Z; Peng Q; Hao L; Guo Y; Zhou W; Cui Q; Shi X
Mol Cell Biochem; 2020 Dec; 475(1-2):79-91. PubMed ID: 32761300
[TBL] [Abstract][Full Text] [Related]
6. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
[TBL] [Abstract][Full Text] [Related]
7. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Yang M; Liu P; Wang K; Glorieux C; Hu Y; Wen S; Jiang W; Huang P
Mol Oncol; 2017 Apr; 11(4):358-372. PubMed ID: 28218497
[TBL] [Abstract][Full Text] [Related]
9. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
10. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
J Immunol; 2004 Oct; 173(8):4919-28. PubMed ID: 15470033
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
[TBL] [Abstract][Full Text] [Related]
12. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.
He YF; Wang XH; Zhang GM; Chen HT; Zhang H; Feng ZH
Cancer Immunol Immunother; 2005 Sep; 54(9):891-7. PubMed ID: 15776283
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
15. MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells.
Guégan JP; Ezan F; Théret N; Langouët S; Baffet G
Carcinogenesis; 2013 Jan; 34(1):38-47. PubMed ID: 23042098
[TBL] [Abstract][Full Text] [Related]
16. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
17. Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo.
Liu X; He S; Wu H; Xie H; Zhang T; Deng Z
Environ Health Prev Med; 2019 Dec; 24(1):79. PubMed ID: 31864288
[TBL] [Abstract][Full Text] [Related]
18. Role of ERK1/2 kinase in cisplatin-induced apoptosis in human ovarian carcinoma cells.
Wei SQ; Sui LH; Zheng JH; Zhang GM; Kao YL
Chin Med Sci J; 2004 Jun; 19(2):125-9. PubMed ID: 15250250
[TBL] [Abstract][Full Text] [Related]
19. Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
Lin HY; Chin YT; Nana AW; Shih YJ; Lai HY; Tang HY; Leinung M; Mousa SA; Davis PJ
Steroids; 2016 Oct; 114():59-67. PubMed ID: 27221508
[TBL] [Abstract][Full Text] [Related]
20. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
